CompScripts

07/15/2024

05/02/2022

May this Eid bring happiness to your heart and your family. Eid-ul-Fitr Mubarak! Wishing you a very Happy Eid Mubarak. Cherish every moment of this beautiful festival and know that all your dreams will come true soon.

03/22/2022

PARP Inhibitors Play Important Role in Frontline, Recurrent Maintenance Treatment of Ovarian Cancer

With 9 new poly adenosine diphosphate-ribose polymerase (PARP) inhibitor drugs approved for ovarian cancer over the past 6 years, increasing amounts of data are finding that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

https://ryze.ly/c181abe5

Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

03/22/2022

What Are the Advantages of Social Media for Pharmacy Professionals?

Social media platforms are constantly changing and it is important to keep up with their evolution to optimize usage. Sometimes it is difficult to start. Many individuals only have personal Facebook accounts. What should you post and how often? Should you tweet or retweet? Share an article on LinkedIn or just like a post?

https://ryze.ly/53a3fe10

As the profession moves more toward the internet, it is helpful to know how to best use the various platforms.

03/22/2022

The Pharmacist’s Role in Bleeding Disorders

March is Bleeding Disorders Awareness Month, which gives pharmacists the opportunity to advocate for and honor patients with bleeding disorders. Having a bleeding disorder can put a patient at risk of a hemorrhage and death.

https://ryze.ly/092447d8

Pharmacists are an important part of the care team for patients with bleeding disorders, providing services such as medication counseling and reconciliation.

03/22/2022

How the Classification of Lymphoma Today Can Be Interpreted As a Marriage of Pathology, Genomics

Pharmacy Times interviewed Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, who is receiving the American Society for Investigative Pathology Gold-Headed Cane Award and is presenting an award lecture at the Experimental Biology 2022 conference on the classification of lymphoma in the modern era—a marriage of pathology and genomics.

https://ryze.ly/178ab802

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses her American Society for Investigative Pathology Gold-Headed Cane Award lecture at the Experimental Biology 2022 conference on the classification of lymphoma in the mod...

03/22/2022

Expert: We Are Now in a Time When There Is ‘Widespread Adoption of Biosimilars’ in Health Care

Pharmacy Times interviewed Shannon Hough, director of ClinReview in Clinical Content for McKesson, on the growing shift to biosimilars in oncology, which is impacting patients and practices by reducing the financial burden of oncology treatments and increasing access to therapies resulting in greater medication adherence.

https://ryze.ly/79d70e5f

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the advantages of including pharmacy staff as part of the care team when payer or drug availability challenges arise.

03/22/2022

Implications of Phase 2 Trial Assessing Niraparib in the Treatment of Uterine Serous Carcinoma

Pharmacy Times interviewed Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute and associate professor at Zucker School of Medicine in Hofstra/Northwell, on her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

https://ryze.ly/cb75eb02

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

03/22/2022

Study: Face Mask Use for Short Time After Hitting COVID-19 Vaccine Targets Is Beneficial

Maintaining face mask use in public indoor spaces and on public transportation for at least 2 weeks after COVID-19 vaccination targets are met, with a minimum of 70% coverage, cuts costs and saves lives, according to the results of a modelling study published in The Lancet Public Health.

https://ryze.ly/7d1b2b29

Simulations of disease spread show that wearing masks for at least 2 weeks after achieving goal of a minimum of 70% population coverage saves money and reduces deaths and hospitalizations.

03/22/2022

Clincial Trials Show Niraparib Improves PFS With Tolerable Safety Profile Following Response to Platinum-based Chemotherapy in Ovarian Cancer

Niraparib (Zejula; Zai Lab Limited) showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a tolerable safety profile following a response to platinum-based chemotherapy regardless of biomarker status, according to the results of the phase 3 PRIME study presented at the Society of Gynecologic Oncology (SGO) annual meeting.1 The trial assessed niraparib as maintenance therapy in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, which were collectively termed ovarian cancer for the purposes of the study.

https://ryze.ly/0ca44af7

Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

03/22/2022

FDA Approves Pembrolizumab for MSI‑H/dMMR Advanced Endometrial Carcinoma

The FDA has approved pembrolizumab (Keytruda) as a single agent for the treatment of patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma, and who experienced disease progression after prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.1

https://ryze.ly/442ae501

Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.

03/21/2022

Approaching Treatment of Newly Diagnosed or Recurrent Ovarian Cancer With PARP Inhibitors

Although the era of personalized medicine has arrived, there remains much to be discussed regarding platinum sensitive disease among patients with newly diagnosed or recurrent ovarian cancer, explained David O’Malley, MD, during a presentation at the Society of Gynecologic Oncology annual meeting. When looking at some of the market data, only approximately 40% of patients with platinum sensitive disease are receiving a poly (ADP-ribose) polymerase (PARP) inhibitor in the first-line setting.

https://ryze.ly/7d8d3cc6

Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.